glp-1 receptor agonist manufacturers must adapt to growing and GIP/GLP-1 agonists markets top glp 1 drug companies
Description
Patients with diabetes already face elevated pancreatitis risk due to obesity, hypertriglyceridemia, and metabolic syndromeconditions common among those prescribed GLP-1 medications
Young: I think, is around the average they see
Gut-brain axis restoration
Endocrinology 158: 4139-4151, 2017
Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial
Results showed that efinopegdutide was more effective in reducing LFC compared to semaglutide
